Name | ONO-AE3-208 |
Description | ONO-AE3-208 (AE 3-208) is an EP4 antagonist. It suppresses cell migration, invasion, and metastasis of prostate cancer. |
In vitro | ONO-AE3-208 abolishes CTGF in the presence of the EET synthesis inhibitor MS-PPOH. Arachidonic acid causes the dose-dependent dilation of the attached Af-Art, and this effect is blocked by ONO-AE3-208 [2]. |
In vivo | In mice, ONO-AE3-208 significantly reduces bone metastasis of PC3 cells in vivo, as evidenced by reduced photon tumor burdens over time when compared to the control group. Additionally, the rate of metastasis is significantly lower in the ONO-AE3-208-treated group, with a median metastasis formation time of 29 days, compared to 21 days in the control group. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : Insoluble DMSO : 70 mg/mL (173.08 mM), Sonication is recommended.
|
Keywords | ONOAE3208 | ONO AE3 208 | Prostaglandin Receptor | inhibit | ONO-AE-3-208 | Inhibitor | ONO-AE3-208 |
Inhibitors Related | Angoroside C | Pranoprofen | Tranilast | Benorilate | Rutin | Ozagrel | Ethamsylate | Rebamipide | Evodiamine | Tebufelone | Timapiprant | p-Hydroxycinnamic acid |
Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |